Late bacille Calmette–Guérin infection with a large focal urinary bladder ulceration as a complication of bladder cancer treatment

Study Type – Therapy (case series) 
Level of Evidence 4 What's known on the subject? and What does the study add? Intravesical BCG treatment has been used worldwide for many decades but there are only a few published reports on persisting BCG infection of the urinary bladder. This is the first...

Full description

Saved in:
Bibliographic Details
Published inBJU international Vol. 107; no. 10; pp. 1592 - 1597
Main Authors Ströck, Viveka, Dotevall, Leif, Sandberg, Torsten, Gustafsson, Christina Kåbjörn, Holmäng, Sten
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.05.2011
Wiley-Blackwell
Subjects
Online AccessGet full text
ISSN1464-4096
1464-410X
1464-410X
DOI10.1111/j.1464-410X.2010.09923.x

Cover

Abstract Study Type – Therapy (case series) 
Level of Evidence 4 What's known on the subject? and What does the study add? Intravesical BCG treatment has been used worldwide for many decades but there are only a few published reports on persisting BCG infection of the urinary bladder. This is the first report on large tuberculosis‐like ulcers of the urinary bladder after intravesical BCG treatment. The finding results in a recommendation to take urine cultures for mycobacteriae in patients with unclear inflammatory lesions in the bladder after instillation of BCG. OBJECTIVE •  To report a late bacille Calmette–Guérin (BCG) complication previously not described in the literature. PATIENTS AND METHODS •  We reviewed our database with 858 patients treated with BCG from 1986 to 2008 and identified 13 male patients (1.8% of all male patients) who had a large tuberculous‐like bladder ulcer. RESULTS •  All patients had high‐grade tumours and seven had tumours invading lamina propria before BCG treatment. A solitary ulceration or inflammatory lesion, 10–50 mm in diameter, was seen at routine follow‐up cystoscopy 2–34 months (median 8 months) after the first instillation. Significantly more patients had been treated with BCG‐RIVM than with BCG‐Tice (10/320 vs. three of 454, P < 0.01). BCG was cultured from urine 3–34 months (median 14 months) after the last instillation. •  So far, eight patients have been successfully treated with rifampicin and isoniazid. Nine patients are still tumour‐free 15–66 months (median 44 months) after the last transurethral resection before BCG treatment. •  Another three patients had one to two non‐invasive recurrences. One patient had an invasive recurrence and underwent cystectomy. The present study is limited by biases associated with its retrospective design. CONCLUSIONS •  This is the first report on persisting BCG infections with large inflammatory lesions in the bladder. Treatment is effective and the oncological outcome is good. •  Mycobacterial cultures of the urine should be performed in BCG‐patients with unclear inflammatory lesions in the bladder since a delayed diagnosis of a persistent BCG infection could result in a permanently reduced bladder capacity. •  Large studies are warranted to study differences in efficacy and side‐effects between different BCG strains.
AbstractList Study Type – Therapy (case series) 
Level of Evidence 4 What's known on the subject? and What does the study add? Intravesical BCG treatment has been used worldwide for many decades but there are only a few published reports on persisting BCG infection of the urinary bladder. This is the first report on large tuberculosis‐like ulcers of the urinary bladder after intravesical BCG treatment. The finding results in a recommendation to take urine cultures for mycobacteriae in patients with unclear inflammatory lesions in the bladder after instillation of BCG. OBJECTIVE •  To report a late bacille Calmette–Guérin (BCG) complication previously not described in the literature. PATIENTS AND METHODS •  We reviewed our database with 858 patients treated with BCG from 1986 to 2008 and identified 13 male patients (1.8% of all male patients) who had a large tuberculous‐like bladder ulcer. RESULTS •  All patients had high‐grade tumours and seven had tumours invading lamina propria before BCG treatment. A solitary ulceration or inflammatory lesion, 10–50 mm in diameter, was seen at routine follow‐up cystoscopy 2–34 months (median 8 months) after the first instillation. Significantly more patients had been treated with BCG‐RIVM than with BCG‐Tice (10/320 vs. three of 454, P < 0.01). BCG was cultured from urine 3–34 months (median 14 months) after the last instillation. •  So far, eight patients have been successfully treated with rifampicin and isoniazid. Nine patients are still tumour‐free 15–66 months (median 44 months) after the last transurethral resection before BCG treatment. •  Another three patients had one to two non‐invasive recurrences. One patient had an invasive recurrence and underwent cystectomy. The present study is limited by biases associated with its retrospective design. CONCLUSIONS •  This is the first report on persisting BCG infections with large inflammatory lesions in the bladder. Treatment is effective and the oncological outcome is good. •  Mycobacterial cultures of the urine should be performed in BCG‐patients with unclear inflammatory lesions in the bladder since a delayed diagnosis of a persistent BCG infection could result in a permanently reduced bladder capacity. •  Large studies are warranted to study differences in efficacy and side‐effects between different BCG strains.
• To report a late bacille Calmette-Guérin (BCG) complication previously not described in the literature. • We reviewed our database with 858 patients treated with BCG from 1986 to 2008 and identified 13 male patients (1.8% of all male patients) who had a large tuberculous-like bladder ulcer. • All patients had high-grade tumours and seven had tumours invading lamina propria before BCG treatment. A solitary ulceration or inflammatory lesion, 10-50 mm in diameter, was seen at routine follow-up cystoscopy 2-34 months (median 8 months) after the first instillation. Significantly more patients had been treated with BCG-RIVM than with BCG-Tice (10/320 vs. three of 454, P < 0.01). BCG was cultured from urine 3-34 months (median 14 months) after the last instillation. • So far, eight patients have been successfully treated with rifampicin and isoniazid. Nine patients are still tumour-free 15-66 months (median 44 months) after the last transurethral resection before BCG treatment. • Another three patients had one to two non-invasive recurrences. One patient had an invasive recurrence and underwent cystectomy. The present study is limited by biases associated with its retrospective design. • This is the first report on persisting BCG infections with large inflammatory lesions in the bladder. Treatment is effective and the oncological outcome is good. • Mycobacterial cultures of the urine should be performed in BCG-patients with unclear inflammatory lesions in the bladder since a delayed diagnosis of a persistent BCG infection could result in a permanently reduced bladder capacity. • Large studies are warranted to study differences in efficacy and side-effects between different BCG strains.
• To report a late bacille Calmette-Guérin (BCG) complication previously not described in the literature.OBJECTIVE• To report a late bacille Calmette-Guérin (BCG) complication previously not described in the literature.• We reviewed our database with 858 patients treated with BCG from 1986 to 2008 and identified 13 male patients (1.8% of all male patients) who had a large tuberculous-like bladder ulcer.PATIENTS AND METHODS• We reviewed our database with 858 patients treated with BCG from 1986 to 2008 and identified 13 male patients (1.8% of all male patients) who had a large tuberculous-like bladder ulcer.• All patients had high-grade tumours and seven had tumours invading lamina propria before BCG treatment. A solitary ulceration or inflammatory lesion, 10-50 mm in diameter, was seen at routine follow-up cystoscopy 2-34 months (median 8 months) after the first instillation. Significantly more patients had been treated with BCG-RIVM than with BCG-Tice (10/320 vs. three of 454, P < 0.01). BCG was cultured from urine 3-34 months (median 14 months) after the last instillation. • So far, eight patients have been successfully treated with rifampicin and isoniazid. Nine patients are still tumour-free 15-66 months (median 44 months) after the last transurethral resection before BCG treatment. • Another three patients had one to two non-invasive recurrences. One patient had an invasive recurrence and underwent cystectomy. The present study is limited by biases associated with its retrospective design.RESULTS• All patients had high-grade tumours and seven had tumours invading lamina propria before BCG treatment. A solitary ulceration or inflammatory lesion, 10-50 mm in diameter, was seen at routine follow-up cystoscopy 2-34 months (median 8 months) after the first instillation. Significantly more patients had been treated with BCG-RIVM than with BCG-Tice (10/320 vs. three of 454, P < 0.01). BCG was cultured from urine 3-34 months (median 14 months) after the last instillation. • So far, eight patients have been successfully treated with rifampicin and isoniazid. Nine patients are still tumour-free 15-66 months (median 44 months) after the last transurethral resection before BCG treatment. • Another three patients had one to two non-invasive recurrences. One patient had an invasive recurrence and underwent cystectomy. The present study is limited by biases associated with its retrospective design.• This is the first report on persisting BCG infections with large inflammatory lesions in the bladder. Treatment is effective and the oncological outcome is good. • Mycobacterial cultures of the urine should be performed in BCG-patients with unclear inflammatory lesions in the bladder since a delayed diagnosis of a persistent BCG infection could result in a permanently reduced bladder capacity. • Large studies are warranted to study differences in efficacy and side-effects between different BCG strains.CONCLUSIONS• This is the first report on persisting BCG infections with large inflammatory lesions in the bladder. Treatment is effective and the oncological outcome is good. • Mycobacterial cultures of the urine should be performed in BCG-patients with unclear inflammatory lesions in the bladder since a delayed diagnosis of a persistent BCG infection could result in a permanently reduced bladder capacity. • Large studies are warranted to study differences in efficacy and side-effects between different BCG strains.
Study Type - Therapy (case series)
Level of Evidence 4 OBJECTIVE: To report a late bacille Calmette-Guérin (BCG) complication previously not described in the literature. PATIENTS AND METHODS: We reviewed our database with 858 patients treated with BCG from 1986 to 2008 and identified 13 male patients (1.8% of all male patients) who had a large tuberculous-like bladder ulcer. RESULTS: All patients had high-grade tumours and seven had tumours invading lamina propria before BCG treatment. A solitary ulceration or inflammatory lesion, 10-50 mm in diameter, was seen at routine follow-up cystoscopy 2-34 months (median 8 months) after the first instillation. Significantly more patients had been treated with BCG-RIVM than with BCG-Tice (10/320 vs. three of 454, P < 0.01). BCG was cultured from urine 3-34 months (median 14 months) after the last instillation. So far, eight patients have been successfully treated with rifampicin and isoniazid. Nine patients are still tumour-free 15-66 months (median 44 months) after the last transurethral resection before BCG treatment. Another three patients had one to two non-invasive recurrences. One patient had an invasive recurrence and underwent cystectomy. The present study is limited by biases associated with its retrospective design. CONCLUSIONS: This is the first report on persisting BCG infections with large inflammatory lesions in the bladder. Treatment is effective and the oncological outcome is good. Mycobacterial cultures of the urine should be performed in BCG-patients with unclear inflammatory lesions in the bladder since a delayed diagnosis of a persistent BCG infection could result in a permanently reduced bladder capacity. Large studies are warranted to study differences in efficacy and side-effects between different BCG strains.
Author Ströck, Viveka
Holmäng, Sten
Dotevall, Leif
Gustafsson, Christina Kåbjörn
Sandberg, Torsten
Author_xml – sequence: 1
  givenname: Viveka
  surname: Ströck
  fullname: Ströck, Viveka
– sequence: 2
  givenname: Leif
  surname: Dotevall
  fullname: Dotevall, Leif
– sequence: 3
  givenname: Torsten
  surname: Sandberg
  fullname: Sandberg, Torsten
– sequence: 4
  givenname: Christina Kåbjörn
  surname: Gustafsson
  fullname: Gustafsson, Christina Kåbjörn
– sequence: 5
  givenname: Sten
  surname: Holmäng
  fullname: Holmäng, Sten
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24165840$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/21166754$$D View this record in MEDLINE/PubMed
https://gup.ub.gu.se/publication/132360$$DView record from Swedish Publication Index
BookMark eNqNkk2O0zAUxy00iJkpXAF5g1il2HHipAuQoGIGUCU2jMTOenFfiivnA9tRZ3ZsOMGcgnNwE06C07RFYjXe2Pr79z70f--SnLVdi4RQzuY8nlfbOc9klmScfZ2nLKpssUjF_PYRuTh9nB3fbCHPyaX3W8aiIPMn5DzlXMoizy7IzxUEpBVoYy3SJdgGQ8A_P-6vh9-_nGmpaWvUwXQt3ZnwjQK14DZI606DpUMkwN3RysJ6jY4OVqODPQ0-srpremv0pHT1idPQRpAGhxAabMNT8rgG6_HZ4Z6Rm6v3X5YfktXn64_Lt6tEZ0KKBNfAq0KwLM_zEnQJFSuKXHJRwqKo0qLKCw1c5pkQhZAcy7oSWZkDVjUUuq7FjCRTXr_DfqhU70wT-1cdGLUZehWlzaA8Ki5SIVnkX05877rvA_qgGuM1WgstdoNXpRSFLFmEZ-T5gRyqBtenzEenI_DiAICP1tUuWmD8Py6LfZfZWPLNxGnXee-wVtqEvYHBgbGKMzWugNqqcbpqnLQaV0DtV0DdxgTlfwmONR4Q-noK3RmLdw-OU-8-3Ywv8RfIaMwE
CitedBy_id crossref_primary_10_1016_j_acuro_2022_08_001
crossref_primary_10_1016_j_ajur_2022_12_006
crossref_primary_10_1016_j_urology_2019_10_013
crossref_primary_10_1186_s13643_025_02761_y
crossref_primary_10_1016_j_eururo_2020_01_017
crossref_primary_10_3233_BLC_239010
crossref_primary_10_1186_1471_2490_14_11
crossref_primary_10_1016_j_rmr_2017_11_010
crossref_primary_10_1259_bjr_20200025
crossref_primary_10_1080_21681805_2021_1973555
crossref_primary_10_2169_internalmedicine_4659_24
crossref_primary_10_1016_j_euo_2020_05_005
crossref_primary_10_1097_MOU_0b013e3283572fe1
crossref_primary_10_1016_j_acuroe_2022_09_003
crossref_primary_10_1097_MD_0000000000000119
crossref_primary_10_1155_2019_6230409
Cites_doi 10.1111/j.1464-410X.2005.05817.x
10.1016/S0090-4295(96)00507-9
10.1016/S0022-5347(17)41212-2
10.1016/j.ctrv.2009.12.005
10.1111/j.1464-410X.1995.tb07309.x
10.1016/S0022-5347(01)67606-7
10.1080/003655900750016698
10.1111/j.1445-2197.1998.tb04768.x
10.1016/0090-4295(93)90595-2
10.1016/S0022-5347(17)37316-0
10.1080/00365540110077371
10.1046/j.1464-410x.1998.00578.x
10.1016/S0022-5347(05)66410-5
10.1016/S1473-3099(02)00182-2
ContentType Journal Article
Copyright 2010 THE AUTHORS; BJU INTERNATIONAL © 2010 BJU INTERNATIONAL
2015 INIST-CNRS
2010 THE AUTHORS; BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.
Copyright_xml – notice: 2010 THE AUTHORS; BJU INTERNATIONAL © 2010 BJU INTERNATIONAL
– notice: 2015 INIST-CNRS
– notice: 2010 THE AUTHORS; BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.
CorporateAuthor Gothenburg University
Sahlgrenska Academy
Göteborgs universitet
Institutionen för biomedicin, avdelningen för infektionssjukdomar
Institute of Clinical Sciences, Section for Oncology, Radiation Physics, Radiology and Urology, Department of Urology
Sahlgrenska akademin
Institutionen för kliniska vetenskaper, sektionen för onkologi, radiofysik, radiologi och urologi, Avdelningen för urologi
Institute of Biomedicine, Department of Infectious Medicine
CorporateAuthor_xml – name: Institutionen för biomedicin, avdelningen för infektionssjukdomar
– name: Göteborgs universitet
– name: Gothenburg University
– name: Institutionen för kliniska vetenskaper, sektionen för onkologi, radiofysik, radiologi och urologi, Avdelningen för urologi
– name: Sahlgrenska Academy
– name: Institute of Biomedicine, Department of Infectious Medicine
– name: Sahlgrenska akademin
– name: Institute of Clinical Sciences, Section for Oncology, Radiation Physics, Radiology and Urology, Department of Urology
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ADTPV
AOWAS
F1U
DOI 10.1111/j.1464-410X.2010.09923.x
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
SwePub
SwePub Articles
SWEPUB Göteborgs universitet
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1464-410X
EndPage 1597
ExternalDocumentID oai_gup_ub_gu_se_132360
21166754
24165840
10_1111_j_1464_410X_2010_09923_x
BJU9923
Genre article
Multicenter Study
Journal Article
GroupedDBID ---
.3N
.55
.GA
.Y3
05W
0R~
10A
1OC
23N
24P
2WC
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
6P2
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACUHS
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BAWUL
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EAD
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HZI
HZ~
IHE
IX1
J0M
J5H
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
R.K
RJQFR
ROL
RX1
SUPJJ
SV3
TEORI
TUS
UB1
V9Y
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WVDHM
WXI
WXSBR
X7M
XG1
YFH
ZGI
ZXP
~IA
~WT
AAYXX
AEYWJ
AGHNM
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
1OB
7X8
ADTPV
AOWAS
F1U
ID FETCH-LOGICAL-c4363-eda1b73045558ac8ab07756138a97b27b57ca1654337361e8fb3485aebfa7cff3
IEDL.DBID DR2
ISSN 1464-4096
1464-410X
IngestDate Tue Sep 09 21:02:48 EDT 2025
Thu Sep 04 23:51:58 EDT 2025
Mon Jul 21 05:38:09 EDT 2025
Mon Jul 21 09:18:28 EDT 2025
Tue Jul 01 03:49:49 EDT 2025
Thu Apr 24 23:12:09 EDT 2025
Wed Jan 22 16:50:16 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords Nephrology
Late
Urinary system disease
complications
BCG
Urinary tract disease
Malignant tumor
Bladder cancer
Bladder tumor
Urology
Infection
Treatment
Urinary system
Urinary bladder
Complication
Bladder disease
Ulceration
bladder neoplasm
Cystitis
Cancer
Language English
License CC BY 4.0
2010 THE AUTHORS; BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4363-eda1b73045558ac8ab07756138a97b27b57ca1654337361e8fb3485aebfa7cff3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 21166754
PQID 863768032
PQPubID 23479
PageCount 6
ParticipantIDs swepub_primary_oai_gup_ub_gu_se_132360
proquest_miscellaneous_863768032
pubmed_primary_21166754
pascalfrancis_primary_24165840
crossref_citationtrail_10_1111_j_1464_410X_2010_09923_x
crossref_primary_10_1111_j_1464_410X_2010_09923_x
wiley_primary_10_1111_j_1464_410X_2010_09923_x_BJU9923
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate May 2011
PublicationDateYYYYMMDD 2011-05-01
PublicationDate_xml – month: 05
  year: 2011
  text: May 2011
PublicationDecade 2010
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: Oxford
– name: England
PublicationTitle BJU international
PublicationTitleAlternate BJU Int
PublicationYear 2011
Publisher Blackwell Publishing Ltd
Wiley-Blackwell
Publisher_xml – name: Blackwell Publishing Ltd
– name: Wiley-Blackwell
References 1995; 75
2001; 165
2006; 52
2010; 36
2000; 34
1989; 141
2002; 34
1992; 147
1993; 41
2005; 96
2002; 2
1997; 49
1998; 81
1995; 153
2007; 14
1998; 68
e_1_2_7_5_2
e_1_2_7_4_2
e_1_2_7_3_2
e_1_2_7_2_2
e_1_2_7_9_2
e_1_2_7_7_2
e_1_2_7_6_2
e_1_2_7_17_2
e_1_2_7_16_2
e_1_2_7_15_2
e_1_2_7_13_2
e_1_2_7_12_2
e_1_2_7_11_2
e_1_2_7_10_2
Hameed A (e_1_2_7_14_2) 2007; 14
Khanna PC (e_1_2_7_8_2) 2006; 52
References_xml – volume: 165
  start-page: 1765
  year: 2001
  end-page: 8
  article-title: The fate of Bacillus Calmette‐Guérin after intravesical instillation
  publication-title: J Urol
– volume: 153
  start-page: 929
  year: 1995
  end-page: 33
  article-title: A randomized study of intravesical mitomycin C, bacillus Calmette‐Guerin Tice and bacillus Calmette‐Guerin RIVM treatment in pTa‐pT1 papillary carcinoma and carcinoma in situ of the bladder
  publication-title: J Urol
– volume: 2
  start-page: 86
  year: 2002
  end-page: 92
  article-title: BCG‐different strains, different vaccines?
  publication-title: Lancet Infect Dis
– volume: 36
  start-page: 195
  year: 2010
  end-page: 205
  article-title: Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta‐analyses
  publication-title: Cancer Treat Rev
– volume: 141
  start-page: 1197
  year: 1989
  end-page: 8
  article-title: Persistent acid‐fast bacilli following intravesical bacillus Calmette‐Guérin
  publication-title: J Urol
– volume: 68
  start-page: 340
  year: 1998
  end-page: 4
  article-title: Bacillus Calmette‐Guérin (BCG) immunotherapy for bladder cancer: review of complications and their treatment
  publication-title: Aust N Z J Surg
– volume: 81
  start-page: 496
  year: 1998
  end-page: 7
  article-title: Acid‐fast bacilli persisting in the genitourinary tract 3 years after intravesical bacilli Calmette‐Guérin therapy for bladder carcinoma
  publication-title: Br J Urol
– volume: 14
  start-page: 3745
  year: 2007
  end-page: 9
  article-title: Bladder contracture: review for intravesical bacillus Calmette‐Guérin complication
  publication-title: Can J Urol
– volume: 34
  start-page: 233
  year: 2002
  end-page: 4
  article-title: Early PCR detection of Bacille Calmette‐Guérin complications in bladder cancer therapy
  publication-title: Scand J Infect Dis
– volume: 34
  start-page: 95
  year: 2000
  end-page: 101
  article-title: Prospective registration of all patients in a geographical region with newly diagnosed bladder carcinomas during a two‐year period
  publication-title: Scand J Urol Nephrol
– volume: 52
  start-page: 35
  year: 2006
  end-page: 7
  article-title: Virtual cystoscopy: reality in imaging of bladder tuberculosis
  publication-title: J Postgrad Med
– volume: 41
  start-page: 353
  year: 1993
  end-page: 5
  article-title: Bladder contracture following intravesical BCG immunotherapy
  publication-title: Urology
– volume: 49
  start-page: 363
  year: 1997
  end-page: 6
  article-title: Incidence of granulomatous prostatitis and acid‐fast bacilli after intravesical BCG therapy
  publication-title: Urology
– volume: 96
  start-page: 1290
  year: 2005
  end-page: 3
  article-title: Intravesical bacillus Calmette‐Guèrin therapy: experience with a reduced dwell‐time in patients with pronounced side‐effects
  publication-title: BJU Int
– volume: 147
  start-page: 596
  year: 1992
  end-page: 600
  article-title: Incidence and treatment of complications of bacillus Calmette‐Guérin intravesical therapy in superficial bladder cancer
  publication-title: J Urol
– volume: 75
  start-page: 188
  year: 1995
  end-page: 92
  article-title: The persistence of bacille Calmette‐ Guérin in the bladder after intravesical treatment for bladder cancer
  publication-title: Br J Urol
– ident: e_1_2_7_9_2
  doi: 10.1111/j.1464-410X.2005.05817.x
– ident: e_1_2_7_15_2
  doi: 10.1016/S0090-4295(96)00507-9
– ident: e_1_2_7_4_2
  doi: 10.1016/S0022-5347(17)41212-2
– ident: e_1_2_7_3_2
  doi: 10.1016/j.ctrv.2009.12.005
– ident: e_1_2_7_5_2
  doi: 10.1111/j.1464-410X.1995.tb07309.x
– ident: e_1_2_7_17_2
  doi: 10.1016/S0022-5347(01)67606-7
– ident: e_1_2_7_2_2
  doi: 10.1080/003655900750016698
– ident: e_1_2_7_7_2
  doi: 10.1111/j.1445-2197.1998.tb04768.x
– volume: 14
  start-page: 3745
  year: 2007
  ident: e_1_2_7_14_2
  article-title: Bladder contracture: review for intravesical bacillus Calmette‐Guérin complication
  publication-title: Can J Urol
– ident: e_1_2_7_13_2
  doi: 10.1016/0090-4295(93)90595-2
– volume: 52
  start-page: 35
  year: 2006
  ident: e_1_2_7_8_2
  article-title: Virtual cystoscopy: reality in imaging of bladder tuberculosis
  publication-title: J Postgrad Med
– ident: e_1_2_7_10_2
  doi: 10.1016/S0022-5347(17)37316-0
– ident: e_1_2_7_12_2
  doi: 10.1080/00365540110077371
– ident: e_1_2_7_6_2
  doi: 10.1046/j.1464-410x.1998.00578.x
– ident: e_1_2_7_11_2
  doi: 10.1016/S0022-5347(05)66410-5
– ident: e_1_2_7_16_2
  doi: 10.1016/S1473-3099(02)00182-2
SSID ssj0014665
Score 2.1118727
Snippet Study Type – Therapy (case series) 
Level of Evidence 4 What's known on the subject? and What does the study add? Intravesical BCG treatment has been used...
• To report a late bacille Calmette-Guérin (BCG) complication previously not described in the literature. • We reviewed our database with 858 patients treated...
• To report a late bacille Calmette-Guérin (BCG) complication previously not described in the literature.OBJECTIVE• To report a late bacille Calmette-Guérin...
Study Type - Therapy (case series)
Level of Evidence 4 OBJECTIVE: To report a late bacille Calmette-Guérin (BCG) complication previously not described in the...
SourceID swepub
proquest
pubmed
pascalfrancis
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1592
SubjectTerms Administration, Intravesical
Aged
Aged, 80 and over
Antibiotics, Antitubercular - therapeutic use
Antineoplastic Agents - adverse effects
Bacterial diseases
BCG
BCG Vaccine - adverse effects
Biological and medical sciences
bladder neoplasm
complications
Cystectomy
cystitis
Epidemiologic Methods
Human bacterial diseases
Humans
Infectious diseases
Male
Medical sciences
Microbiology in the medical area
Middle Aged
Mikrobiologi inom det medicinska området
Mycobacterium bovis - isolation & purification
Nephrology. Urinary tract diseases
Tuberculosis and atypical mycobacterial infections
Tuberculosis, Urogenital - drug therapy
Tuberculosis, Urogenital - etiology
Tuberculosis, Urogenital - urine
Tumors of the urinary system
Urinary Bladder - microbiology
Urinary Bladder Neoplasms - drug therapy
Urinary Bladder Neoplasms - surgery
Urinary tract. Prostate gland
Urologi och njurmedicin
Urology and Nephrology
Title Late bacille Calmette–Guérin infection with a large focal urinary bladder ulceration as a complication of bladder cancer treatment
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1464-410X.2010.09923.x
https://www.ncbi.nlm.nih.gov/pubmed/21166754
https://www.proquest.com/docview/863768032
https://gup.ub.gu.se/publication/132360
Volume 107
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NjtMwELbQHhAS4h82_Kx8QNxSxbETO0dYWFYrlgOiUm-W7dortFVaNYmEOHHhCXgKnoM34UmYidNAVntYIS5RlXiadDqT-ez5PEPI82WeyWB7dj8cRKiq1Ba2SpUH9AwTImMcrkOevi-P5-JkUSwG_hPuhYn1IcYFN_SM_n2NDm5sc9HJRSpYthgYWhWAlRniScZLLKP_-sNYSQqG9l0lowjA9imp59IvmkSqmxvTgNJC7HZxGRwda41OYW4fp45uk_PdL4z0lPNZ19qZ-3Kh-OP_UcEdcmuAs_RltL-75Jqv75Hrp0PC_j759g6wLLXG4ZZDeojNWtrW__r6_W3388f2U013ZLCa4oowNXSF1HQaMMRSzATA01G7wvfjlnYr56PFUtPA2L_58HQdxnEOTXlLRxL9AzI_evPx8DgdOj-kTmBi2S8NsxKTuEWhjFPGYqU-QB7KVNLm0hbSGdyHxbnkJfMqWC5UYbwNRroQ-EOyV69rv0-oswUE3CCYNYXIl9JKxW259K5yMhNeJUTu_mXthrLo2J1jpSfTI6FRyxq1rHst688JYaPkJpYGuYLMwcSQRkEAUogFs4TQnWVpcHTM3pjar7tGqxJigcp4npBH0eL-CDNWwsRPJORFNMHxChYPP-s2Gk6ddbrxmvGcl3CXsrerKz-3fnUyx0-P_1XwCbkRV-ORKvqU7LXbzj8DONfag95RfwMrlD4n
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtNAEF6hVgIkxP-P-Sl7QNwc-WftXR-hooSS9IAaKbfV7ma3qrCcKLElxIkLT9Cn6HP0TXgSZryOwVUPFeISRclO4kxmPN_OfDtDyJtFEnGnW3Y_PDBXFKHOdBEKC-gZNkRKGcxDTo_y8YwdzrN5Nw4Iz8L4_hB9wg09o71fo4NjQvqyl7OQxdG8o2gVgFZGACh323IdIqQvfS8pWNvOlfQyANyHtJ4rP2kQq-6s1AbU5vy8i6sAad9tdAh020h1cI-U29_oCSpfR02tR-b7pfaP_0kJ98ndDtHSd94EH5AbtnpIbk67mv0j8nMCcJZqZfDUId3HeS11bX_9OPvYXJyvTyu65YNVFJPCVNES2enUYZSlWAyAy6O6xFvkmjalsd5oqdrA2r8p8XTp-nUGrXlNex79YzI7-HC8Pw674Q-hYVhbtgsVa4513CwTygilsVkfgA-hCq4TrjNuFB7FSlOe5rEVTqdMZMpqp7hxLn1CdqplZZ8RanQGMdexWKuMJQuuuUh1vrCmMDxiVgSEb_9mabrO6Digo5SDHRKTqGWJWpatluW3gMS95Mp3B7mGzN7AknpBwFIIB6OA0K1pSfB1LOCoyi6bjRQ5hAMRpUlAnnqT-yMcxzns_VhA3nob7N_B_uEnzUrCSyeN3FgZp0maw7fkrWFd-7rl-8MZPnv-r4Kvya3x8XQiJ5-OPr8gt31yHpmjL8lOvW7sK0B3td5rvfY3AXJCRQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NatwwEBYlgVAo_f9xf1IdSm9e_CNb8jFNu03TJJTShb0JSZZCyOJddm0oOeWSJ8hT9Dn6Jn2Szlhetw45hNKLWWzN2js74_mk-TRDyJsyibjTLbsfDswVRagzXYTCAnqGCZFSBtchD4_yvQnbn2bTjv-Ee2F8fYh-wQ09o31fo4MvSnfVyVnI4mjaMbQKACsjwJObLIeoiQDpa19KCsa2bSW9DOD2Iavn2m8ahKo7C7UCrTnf7uI6PNoXGx3i3DZQje-R0_VP9PyU01FT65E5u1L98f_o4D652-FZuuMN8AG5ZauHZOuwy9g_IhcHAGapVgb3HNJd7NZS1_bX-eXH5ueP5UlF12ywiuKSMFV0htx06jDGUkwFwNNRPcMX5JI2M2O9yVK1grF_E-Lp3PXjDNrykvYs-sdkMv7wbXcv7Fo_hIZhZtmWKtYcs7hZJpQRSmOpPoAeQhVcJ1xn3CjciJWmPM1jK5xOmciU1U5x41z6hGxU88o-I9ToDCKuY7FWGUtKrrlIdV5aUxgeMSsCwtf_sjRdXXRszzGTg_kRk6hliVqWrZbl94DEveTC1wa5gcz2wJB6QUBSCAajgNC1ZUnwdEzfqMrOm5UUOQQDEaVJQJ56i_sjHMc5zPxYQN56E-yvYPXw42Yh4dRxI1dWxmmS5nCXvLWrGz-3fLc_wU_P_1XwNdn68n4sDz4dfX5BbvuVeaSNviQb9bKxrwDa1Xq79dnf_TJA9A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Late+bacille+Calmette%E2%80%93Gu%C3%A9rin+infection+with+a+large+focal+urinary+bladder+ulceration+as+a+complication+of+bladder+cancer+treatment&rft.jtitle=BJU+international&rft.au=Str%C3%B6ck%2C+Viveka&rft.au=Dotevall%2C+Leif&rft.au=Sandberg%2C+Torsten&rft.au=Gustafsson%2C+Christina+K%C3%A5bj%C3%B6rn&rft.date=2011-05-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=1464-4096&rft.eissn=1464-410X&rft.volume=107&rft.issue=10&rft.spage=1592&rft.epage=1597&rft_id=info:doi/10.1111%2Fj.1464-410X.2010.09923.x&rft.externalDBID=10.1111%252Fj.1464-410X.2010.09923.x&rft.externalDocID=BJU9923
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon